SEARCH

SEARCH BY CITATION

References

  • 1
    Sjöblom L, Hårdemark HG, Lindgren A, Norrving B, Fahlén M, Samuelsson M, Stigendal L, Stockelberg D, Taghavi A, Wallrup L, Wallvik J. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001; 32: 256774.
  • 2
    Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 4238.
  • 3
    Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 268592.
  • 4
    Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC, Ansell JE, Mayer SA, Norrving B, Rosand J, Steiner T, Wijdicks EF, Yamaguchi T, Yasaka M. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007; 82: 8292.
  • 5
    Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692711.
  • 6
    Executive Committee and Scientific Advisory Committee of the Federal Physicians Chamber. Prothrombin complex concentrate. In: Guidelines for Therapy with Blood Components and Plasma Derivatives, 2nd edn. Köln: Deutscher Ärzte-Verlag GmbH, 2002: 95111.
  • 7
    Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204S33S.
  • 8
    Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 4927.
  • 9
    O’Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 1128.
  • 10
    Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition – 2005 update. Br J Haematol 2006; 132: 27785.
  • 11
    Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 47780.
  • 12
    Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14: 45861.
  • 13
    Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115: 4559.
  • 14
    Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol 2001; 114: 27180.
  • 15
    Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev 2007; 21: 3748.
  • 16
    Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006; 67: 12724.
  • 17
    Khan H, Belsher J, Yilmaz M, Afessa B, Winters JL, Moore SB, Hubmayr RD, Gajic O. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007; 131: 130814.
  • 18
    Römisch J, Gröner A, Bernhardt D, Diehl KH, Hein B, List W, Müller HG, Nowak T, Ronneberger H, Schüler E, Weimer T, Hilfenhaus J. Nanofiltration bei der Herstellung von Beriplex® P/N: Erhöhung der Kapazität zur Viruseliminierung unter Beibehaltung der Produktqualität. Beitr Infusionsther Transfusionsmed 1996; 33: 2204.
  • 19
    Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 96770.
  • 20
    Spence RK. Clinical use of plasma and plasma fractions. Best Pract Res Clin Haematol 2006; 19: 8396.
  • 21
    Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex® P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost 2007; 98: 7907.
  • 22
    Evans G, Luddington R, Baglin T. Beriplex® P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001; 115: 9981001.
  • 23
    Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex®): efficacy and safety in 42 patients. Br J Haematol 2002; 116: 61924.
  • 24
    Stephens EA, Lee D, Brown S, Parapia L. The use of a prothrombin complex (Beriplex®) to reverse oral anticoagulation and other clotting abnormalities – a three year audit. Presented at European Hematology Association 7th Annual Congress, Florence, Italy, June 7–9, 2002.
  • 25
    Sharples R, Burnett C, Murphy M, Hanley JP. Prospective evaluation of a regional protocol for a rapid warfarin reversal in major haemorrhage. Br J Haematol 2003; 121(Suppl. 1): 34.
  • 26
    Lorenz R, Kienast J, Otto U, Kiehl M, Schreiter D, Haertel S, Barthels M. Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study. Blood Coagul Fibrinolysis 2007; 18: 56570.
  • 27
    Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B, Locker GJ, Laczika K, Knapp S, Watzke H. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med 1999; 25: 110510.
  • 28
    Lorenz R, Kienast J, Otto U, Egger K, Kiehl M, Schreiter D, Kwasny H, Haertel S, Barthels M. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol 2003; 15: 1520.
  • 29
    Koreth R, Weinert C, Weisdorf DJ, Key NS. Measurement of bleeding severity: a critical review. Transfusion 2004; 44: 60517.
  • 30
    Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121: 916.
  • 31
    Demeyere R, Arnout J, Strengers P. Prothrombin complex concentrate versus fresh frozen plasma in patients on oral anticoagulant therapy undergoing cardiac surgery: a randomized study. Crit Care 2006; 10(Suppl. 1): S978.
  • 32
    Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37: 146570.
  • 33
    Vigué B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, Martin L, Benhamou D. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33: 7215.
  • 34
    Van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thromb Res 2006; 118: 31320.
  • 35
    Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, Brenner B. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004; 113: 3718.
  • 36
    Gadisseur AP, Van Der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002; 117: 9406.
  • 37
    Rodewald L, Scharrer I. Protein chemical investigation of 30 consecutive lots of double-virus eliminated PCC (Beriplex® P/N) and summary of safety data. Hämostaseologie 2004; 24: A46.
  • 38
    Yasaka M, Oomura M, Ikeno K, Naritomi H, Minematsu K. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol 2003; 82: 1213.
  • 39
    Fraser TA, Corke CF, Mohajeri M, Stevenson L, Campbell PJ. A retrospective audit of the use of Prothrombinex-HT for refractory bleeding following adult cardiac surgery. Crit Care Resusc 2006; 8: 1415.
  • 40
    Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 95: S137.
  • 41
    Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res 2002; 105: 391400.
  • 42
    Appelboam R, Thomas EO. The headache over warfarin in British neurosurgical intensive care units: a national survey of current practice. Intensive Care Med 2007; 33: 194653.
  • 43
    Makris M. Optimisation of the prothrombin complex concentrate dose for warfarin reversal. Thromb Res 2005; 115: 4513.